StemRIM (JPX: 4599.T) Stock Competitors & Peer Comparison
See 4599.T's competitors and their performance on the JPX and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for 4599.T and its JPX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 4599.T | ¥357.00 | +0.56% | 22.4B | -11.93 | -¥29.92 | N/A |
| 2160.T | ¥2,786.00 | -5.53% | 183.3B | -24.94 | -¥111.72 | N/A |
| 4587.T | ¥1,114.50 | +1.18% | 143.2B | -40.32 | -¥27.64 | N/A |
| 4565.T | ¥1,103.00 | -2.65% | 101.2B | -12.77 | -¥86.36 | N/A |
| 4588.T | ¥3,380.00 | -9.14% | 99B | -63.55 | -¥53.19 | N/A |
| 4592.T | ¥1,010.00 | -3.07% | 78.8B | -24.12 | -¥41.88 | N/A |
| 219A.T | ¥2,229.00 | -1.98% | 51B | N/A | N/A | N/A |
| 4894.T | ¥5,190.00 | -1.33% | 42.9B | -37.52 | -¥138.34 | N/A |
| 4593.T | ¥270.00 | -6.25% | 36.5B | -11.17 | -¥24.18 | N/A |
| 7774.T | ¥862.00 | +3.61% | 35B | -79.37 | -¥10.86 | N/A |
Stock Comparison
GNI Group Ltd. (JPX: 2160.T)
4599.T vs 2160.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 2160.T has a market cap of 183.3B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 2160.T trades at ¥2,786.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 2160.T's P/E ratio is -24.94. In terms of profitability, 4599.T's ROE is -0.28%, compared to 2160.T's ROE of -0.12%. Regarding short-term risk, 4599.T is less volatile compared to 2160.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 2160.T's competition here
PeptiDream Inc. (JPX: 4587.T)
4599.T vs 4587.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4587.T has a market cap of 143.2B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4587.T trades at ¥1,114.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4587.T's P/E ratio is -40.32. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4587.T's ROE of -0.07%. Regarding short-term risk, 4599.T is more volatile compared to 4587.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4587.T's competition here
Nxera Pharma Co., Ltd. (JPX: 4565.T)
4599.T vs 4565.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4565.T has a market cap of 101.2B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4565.T trades at ¥1,103.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4565.T's P/E ratio is -12.77. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4565.T's ROE of -0.12%. Regarding short-term risk, 4599.T is more volatile compared to 4565.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4565.T's competition here
Oncolys BioPharma Inc. (JPX: 4588.T)
4599.T vs 4588.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4588.T has a market cap of 99B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4588.T trades at ¥3,380.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4588.T's P/E ratio is -63.55. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4588.T's ROE of -0.48%. Regarding short-term risk, 4599.T is less volatile compared to 4588.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 4588.T's competition here
SanBio Company Limited (JPX: 4592.T)
4599.T vs 4592.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4592.T has a market cap of 78.8B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4592.T trades at ¥1,010.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4592.T's P/E ratio is -24.12. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4592.T's ROE of -0.45%. Regarding short-term risk, 4599.T is more volatile compared to 4592.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4592.T's competition here
Heartseed, Inc. (JPX: 219A.T)
4599.T vs 219A.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 219A.T has a market cap of 51B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 219A.T trades at ¥2,229.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 219A.T's P/E ratio is N/A. In terms of profitability, 4599.T's ROE is -0.28%, compared to 219A.T's ROE of -0.09%. Regarding short-term risk, 4599.T is less volatile compared to 219A.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 219A.T's competition here
Cuorips Inc. (JPX: 4894.T)
4599.T vs 4894.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4894.T has a market cap of 42.9B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4894.T trades at ¥5,190.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4894.T's P/E ratio is -37.52. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4894.T's ROE of -0.23%. Regarding short-term risk, 4599.T is more volatile compared to 4894.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4894.T's competition here
Healios K.K. (JPX: 4593.T)
4599.T vs 4593.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4593.T has a market cap of 36.5B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4593.T trades at ¥270.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4593.T's P/E ratio is -11.17. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4593.T's ROE of +0.03%. Regarding short-term risk, 4599.T is less volatile compared to 4593.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 4593.T's competition here
Japan Tissue Engineering Co., Ltd. (JPX: 7774.T)
4599.T vs 7774.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 7774.T has a market cap of 35B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 7774.T trades at ¥862.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 7774.T's P/E ratio is -79.37. In terms of profitability, 4599.T's ROE is -0.28%, compared to 7774.T's ROE of -0.08%. Regarding short-term risk, 4599.T is less volatile compared to 7774.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 7774.T's competition here
Innovacell Inc. (JPX: 504A.T)
4599.T vs 504A.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 504A.T has a market cap of 28.6B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 504A.T trades at ¥633.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 504A.T's P/E ratio is -9.25. In terms of profitability, 4599.T's ROE is -0.28%, compared to 504A.T's ROE of N/A. Regarding short-term risk, 4599.T is less volatile compared to 504A.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 504A.T's competition here
Renascience Inc. (JPX: 4889.T)
4599.T vs 4889.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4889.T has a market cap of 17.9B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4889.T trades at ¥1,302.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4889.T's P/E ratio is -55.66. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4889.T's ROE of -0.12%. Regarding short-term risk, 4599.T is less volatile compared to 4889.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 4889.T's competition here
CanBas Co., Ltd. (JPX: 4575.T)
4599.T vs 4575.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4575.T has a market cap of 15.8B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4575.T trades at ¥802.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4575.T's P/E ratio is -12.15. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4575.T's ROE of -0.60%. Regarding short-term risk, 4599.T is less volatile compared to 4575.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 4575.T's competition here
AnGes, Inc. (JPX: 4563.T)
4599.T vs 4563.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4563.T has a market cap of 15.4B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4563.T trades at ¥39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4563.T's P/E ratio is -4.09. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4563.T's ROE of -1.63%. Regarding short-term risk, 4599.T is less volatile compared to 4563.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 4563.T's competition here
ReproCELL Incorporated (JPX: 4978.T)
4599.T vs 4978.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4978.T has a market cap of 14.7B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4978.T trades at ¥150.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4978.T's P/E ratio is -32.61. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4978.T's ROE of -0.05%. Regarding short-term risk, 4599.T is more volatile compared to 4978.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4978.T's competition here
RaQualia Pharma Inc. (JPX: 4579.T)
4599.T vs 4579.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4579.T has a market cap of 13.8B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4579.T trades at ¥565.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4579.T's P/E ratio is 190.08. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4579.T's ROE of +0.02%. Regarding short-term risk, 4599.T is less volatile compared to 4579.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 4579.T's competition here
Stella Pharma Corporation (JPX: 4888.T)
4599.T vs 4888.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4888.T has a market cap of 12.5B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4888.T trades at ¥347.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4888.T's P/E ratio is -14.01. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4888.T's ROE of -0.30%. Regarding short-term risk, 4599.T is more volatile compared to 4888.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4888.T's competition here
MediciNova, Inc. (JPX: 4875.T)
4599.T vs 4875.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4875.T has a market cap of 10.6B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4875.T trades at ¥216.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4875.T's P/E ratio is -5.69. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4875.T's ROE of -0.27%. Regarding short-term risk, 4599.T is more volatile compared to 4875.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4875.T's competition here
Immuno-Biological Laboratories Co., Ltd. (JPX: 4570.T)
4599.T vs 4570.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4570.T has a market cap of 10.1B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4570.T trades at ¥1,080.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4570.T's P/E ratio is 27.31. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4570.T's ROE of +0.21%. Regarding short-term risk, 4599.T is less volatile compared to 4570.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 4570.T's competition here
SUSMED,Inc. (JPX: 4263.T)
4599.T vs 4263.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4263.T has a market cap of 9.7B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4263.T trades at ¥576.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4263.T's P/E ratio is -25.36. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4263.T's ROE of -0.09%. Regarding short-term risk, 4599.T is more volatile compared to 4263.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4263.T's competition here
Kubota Pharmaceutical Holdings Co., Ltd. (JPX: 4596.T)
4599.T vs 4596.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4596.T has a market cap of 9.5B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4596.T trades at ¥68.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4596.T's P/E ratio is -7.41. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4596.T's ROE of -0.51%. Regarding short-term risk, 4599.T is more volatile compared to 4596.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4596.T's competition here
CellSeed Inc. (JPX: 7776.T)
4599.T vs 7776.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 7776.T has a market cap of 9.1B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 7776.T trades at ¥233.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 7776.T's P/E ratio is -8.41. In terms of profitability, 4599.T's ROE is -0.28%, compared to 7776.T's ROE of -0.67%. Regarding short-term risk, 4599.T is more volatile compared to 7776.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 7776.T's competition here
NANO MRNA Co.,Ltd. (JPX: 4571.T)
4599.T vs 4571.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4571.T has a market cap of 9B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4571.T trades at ¥108.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4571.T's P/E ratio is -8.37. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4571.T's ROE of -0.34%. Regarding short-term risk, 4599.T is more volatile compared to 4571.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4571.T's competition here
K Pharma,Inc. (JPX: 4896.T)
4599.T vs 4896.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4896.T has a market cap of 8.8B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4896.T trades at ¥761.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4896.T's P/E ratio is -8.46. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4896.T's ROE of -0.90%. Regarding short-term risk, 4599.T is more volatile compared to 4896.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4896.T's competition here
Kidswell Bio Corporation (JPX: 4584.T)
4599.T vs 4584.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4584.T has a market cap of 8.4B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4584.T trades at ¥170.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4584.T's P/E ratio is -21.57. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4584.T's ROE of -0.20%. Regarding short-term risk, 4599.T is more volatile compared to 4584.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4584.T's competition here
OncoTherapy Science, Inc. (JPX: 4564.T)
4599.T vs 4564.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4564.T has a market cap of 8.4B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4564.T trades at ¥21.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4564.T's P/E ratio is -8.90. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4564.T's ROE of -0.43%. Regarding short-term risk, 4599.T is less volatile compared to 4564.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 4564.T's competition here
StemCell Institute Inc. (JPX: 7096.T)
4599.T vs 7096.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 7096.T has a market cap of 7.8B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 7096.T trades at ¥775.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 7096.T's P/E ratio is 52.83. In terms of profitability, 4599.T's ROE is -0.28%, compared to 7096.T's ROE of +0.06%. Regarding short-term risk, 4599.T is more volatile compared to 7096.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 7096.T's competition here
Carna Biosciences, Inc. (JPX: 4572.T)
4599.T vs 4572.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4572.T has a market cap of 7.7B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4572.T trades at ¥403.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4572.T's P/E ratio is -3.53. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4572.T's ROE of -14.32%. Regarding short-term risk, 4599.T is more volatile compared to 4572.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4572.T's competition here
MEDINET Co., Ltd. (JPX: 2370.T)
4599.T vs 2370.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 2370.T has a market cap of 7.3B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 2370.T trades at ¥26.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 2370.T's P/E ratio is -6.44. In terms of profitability, 4599.T's ROE is -0.28%, compared to 2370.T's ROE of -0.31%. Regarding short-term risk, 4599.T is less volatile compared to 2370.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 2370.T's competition here
CellSource Co., Ltd. (JPX: 4880.T)
4599.T vs 4880.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4880.T has a market cap of 7.1B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4880.T trades at ¥356.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4880.T's P/E ratio is 99.75. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4880.T's ROE of +0.01%. Regarding short-term risk, 4599.T is more volatile compared to 4880.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4880.T's competition here
ADR120S, Inc. (JPX: 3750.T)
4599.T vs 3750.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 3750.T has a market cap of 6.8B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 3750.T trades at ¥764.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 3750.T's P/E ratio is -12.17. In terms of profitability, 4599.T's ROE is -0.28%, compared to 3750.T's ROE of -6.59%. Regarding short-term risk, 4599.T is more volatile compared to 3750.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 3750.T's competition here
PRISM BioLab Co.,LTD (JPX: 206A.T)
4599.T vs 206A.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 206A.T has a market cap of 6.3B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 206A.T trades at ¥170.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 206A.T's P/E ratio is -7.17. In terms of profitability, 4599.T's ROE is -0.28%, compared to 206A.T's ROE of -0.38%. Regarding short-term risk, 4599.T is more volatile compared to 206A.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 206A.T's competition here
Noile-Immune Biotech Inc. (JPX: 4893.T)
4599.T vs 4893.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4893.T has a market cap of 6.2B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4893.T trades at ¥144.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4893.T's P/E ratio is -8.27. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4893.T's ROE of -0.20%. Regarding short-term risk, 4599.T is more volatile compared to 4893.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4893.T's competition here
Chordia Therapeutics Inc. (JPX: 190A.T)
4599.T vs 190A.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 190A.T has a market cap of 6.2B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 190A.T trades at ¥82.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 190A.T's P/E ratio is -2.83. In terms of profitability, 4599.T's ROE is -0.28%, compared to 190A.T's ROE of -0.61%. Regarding short-term risk, 4599.T is more volatile compared to 190A.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 190A.T's competition here
Chiome Bioscience Inc. (JPX: 4583.T)
4599.T vs 4583.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4583.T has a market cap of 6.1B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4583.T trades at ¥84.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4583.T's P/E ratio is -6.41. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4583.T's ROE of -0.71%. Regarding short-term risk, 4599.T is more volatile compared to 4583.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4583.T's competition here
Soiken Holdings Inc. (JPX: 2385.T)
4599.T vs 2385.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 2385.T has a market cap of 5.8B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 2385.T trades at ¥220.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 2385.T's P/E ratio is 31.25. In terms of profitability, 4599.T's ROE is -0.28%, compared to 2385.T's ROE of +0.03%. Regarding short-term risk, 4599.T is more volatile compared to 2385.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 2385.T's competition here
Cyfuse Biomedical K.K. (JPX: 4892.T)
4599.T vs 4892.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4892.T has a market cap of 5.7B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4892.T trades at ¥565.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4892.T's P/E ratio is -6.94. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4892.T's ROE of -0.29%. Regarding short-term risk, 4599.T is more volatile compared to 4892.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4892.T's competition here
D. Western Therapeutics Institute, Inc. (JPX: 4576.T)
4599.T vs 4576.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4576.T has a market cap of 5.1B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4576.T trades at ¥88.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4576.T's P/E ratio is -7.42. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4576.T's ROE of -0.45%. Regarding short-term risk, 4599.T is more volatile compared to 4576.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4576.T's competition here
TMS Co., Ltd. (JPX: 4891.T)
4599.T vs 4891.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4891.T has a market cap of 5B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4891.T trades at ¥110.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4891.T's P/E ratio is -7.47. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4891.T's ROE of -0.32%. Regarding short-term risk, 4599.T is more volatile compared to 4891.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4891.T's competition here
J-Pharma Co.,Ltd. (JPX: 520A.T)
4599.T vs 520A.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 520A.T has a market cap of 4.9B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 520A.T trades at ¥275.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 520A.T's P/E ratio is -2.01. In terms of profitability, 4599.T's ROE is -0.28%, compared to 520A.T's ROE of N/A. Regarding short-term risk, 4599.T is more volatile compared to 520A.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 520A.T's competition here
Ribomic Inc. (JPX: 4591.T)
4599.T vs 4591.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4591.T has a market cap of 4.5B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4591.T trades at ¥81.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4591.T's P/E ratio is -3.51. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4591.T's ROE of -0.39%. Regarding short-term risk, 4599.T is more volatile compared to 4591.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4591.T's competition here
BrightPath Biotherapeutics Co., Ltd. (JPX: 4594.T)
4599.T vs 4594.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4594.T has a market cap of 4.5B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4594.T trades at ¥53.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4594.T's P/E ratio is -4.10. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4594.T's ROE of -0.93%. Regarding short-term risk, 4599.T is less volatile compared to 4594.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 4594.T's competition here
Kohjin Bio Co., Ltd. (JPX: 177A.T)
4599.T vs 177A.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 177A.T has a market cap of 4.3B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 177A.T trades at ¥846.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 177A.T's P/E ratio is 34.10. In terms of profitability, 4599.T's ROE is -0.28%, compared to 177A.T's ROE of +0.02%. Regarding short-term risk, 4599.T is more volatile compared to 177A.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 177A.T's competition here
Trans Genic Inc. (JPX: 2342.T)
4599.T vs 2342.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 2342.T has a market cap of 4.3B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 2342.T trades at ¥257.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 2342.T's P/E ratio is 134.55. In terms of profitability, 4599.T's ROE is -0.28%, compared to 2342.T's ROE of +0.01%. Regarding short-term risk, 4599.T is more volatile compared to 2342.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 2342.T's competition here
Kringle Pharma, Inc. (JPX: 4884.T)
4599.T vs 4884.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4884.T has a market cap of 3.5B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4884.T trades at ¥430.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4884.T's P/E ratio is -3.91. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4884.T's ROE of -0.68%. Regarding short-term risk, 4599.T is more volatile compared to 4884.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4884.T's competition here
Human Metabolome Technologies, Inc. (JPX: 6090.T)
4599.T vs 6090.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 6090.T has a market cap of 3.4B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 6090.T trades at ¥612.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 6090.T's P/E ratio is 17.15. In terms of profitability, 4599.T's ROE is -0.28%, compared to 6090.T's ROE of +0.11%. Regarding short-term risk, 4599.T is more volatile compared to 6090.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 6090.T's competition here
Modalis Therapeutics Corporation (JPX: 4883.T)
4599.T vs 4883.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4883.T has a market cap of 3.2B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4883.T trades at ¥33.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4883.T's P/E ratio is -1.37. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4883.T's ROE of -0.76%. Regarding short-term risk, 4599.T is more volatile compared to 4883.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4883.T's competition here
Veritas In Silico Inc. (JPX: 130A.T)
4599.T vs 130A.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 130A.T has a market cap of 2.9B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 130A.T trades at ¥448.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 130A.T's P/E ratio is -6.83. In terms of profitability, 4599.T's ROE is -0.28%, compared to 130A.T's ROE of N/A. Regarding short-term risk, 4599.T is less volatile compared to 130A.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 130A.T's competition here
FunPep Company Limited (JPX: 4881.T)
4599.T vs 4881.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4881.T has a market cap of 2.3B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4881.T trades at ¥51.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4881.T's P/E ratio is -1.28. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4881.T's ROE of -0.92%. Regarding short-term risk, 4599.T is more volatile compared to 4881.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4881.T's competition here
Delta-Fly Pharma, Inc. (JPX: 4598.T)
4599.T vs 4598.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 4598.T has a market cap of 1.6B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 4598.T trades at ¥109.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 4598.T's P/E ratio is -0.78. In terms of profitability, 4599.T's ROE is -0.28%, compared to 4598.T's ROE of -16.78%. Regarding short-term risk, 4599.T is more volatile compared to 4598.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 4598.T's competition here
PhoenixBio Co., Ltd. (JPX: 6190.T)
4599.T vs 6190.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 6190.T has a market cap of 1.4B. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 6190.T trades at ¥346.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 6190.T's P/E ratio is 93.77. In terms of profitability, 4599.T's ROE is -0.28%, compared to 6190.T's ROE of +0.01%. Regarding short-term risk, 4599.T is more volatile compared to 6190.T. This indicates higher risk in terms of short-term price fluctuations for 4599.T.Check 6190.T's competition here
tella, Inc. (JPX: 2191.T)
4599.T vs 2191.T Comparison August 2026
StemRIM (JPX: 4599.T) plays a significant role within the Healthcare sector. Its performance on the JPX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4599.T stands at 22.4B. In comparison, 2191.T has a market cap of 0. Regarding current trading prices, 4599.T is priced at ¥357.00 on the JPX, while 2191.T trades at ¥2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4599.T currently has a P/E ratio of -11.93, whereas 2191.T's P/E ratio is -0.06. In terms of profitability, 4599.T's ROE is -0.28%, compared to 2191.T's ROE of -1.44%. Regarding short-term risk, 4599.T is less volatile compared to 2191.T. This indicates lower risk in terms of short-term price fluctuations for 4599.T.Check 2191.T's competition here